徳島大学 / 教育研究者総覧 --- 前田悠作

検索:

徳島大学 ⟩ 病院 ⟩ 中央診療施設等 ⟩ 徳島県地域医療支援センター ⟩
徳島大学 ⟩ 病院 ⟩ 診療科 ⟩ 内科 ⟩ 血液内科 ⟩

(researchmapへのインポート用ファイル) [PDF解説] [researchmapへの自動反映について]

研究活動

専門分野

研究テーマ

著書・論文

学術論文(審査論文):

1.	Mizuki Yoshimoto, Shin-ichiro Yanagiya, Hiroki Takanari, Takeshi Honda, Yusaku Maeda, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, Takeshi Harada, Shiro Fujii, Shingen Nakamura, Yoshimi Bando, Koichi Tsuneyama, Itsuro Endo, Masahiro Abe, Ken-ichi Matsuoka and Hirokazu Miki : Development of a rapid and novel diagnostic technique for cardiac amyloidosis using Raman spectroscopy., Research Square, 2025. (要約) Although the prognosis of cardiac amyloidosis has improved with the development of therapies, the time required for disease typing remains a critical issue. We investigated the potential of Raman spectroscopy for the more rapid diagnosis and typing of cardiac amyloidosis. Heart biopsies were collected from patients with the AL (4) and ATTR (4) types of cardiac amyloidosis, and tissue sections were subjected to Raman microscopy. A principal component analysis (PCA) of spectral data was performed and receiver operating characteristic (ROC) curves were created to confirm the accuracy of discriminating between amyloid-deposition and non-deposition sites, and between AL and ATTR. The steep peak at 1680 cm-1, reflecting the β-sheet structure, was useful for detecting the amyloid-deposition region. By restricting the spectral analysis to amyloid-deposition sites, AL and ATTR were discriminated by principal components with a characteristic broad peak at 1520-1540 cm-1, which was also observed in the Raman spectrum of AL, but not ATTR. The area under ROC curve discriminating AL and ATTR was 0.78. PCA of the Raman spectra of cardiac biopsies has the potential not only to detect amyloid-deposition sites in tissue but also to rapidly discriminate between the AL and ATTR types of cardiac amyloidosis. (出版サイトへのリンク) ● Publication site (DOI): 10.21203/rs.3.rs-6795517/v1 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 40678255 ● Search Scopus @ Elsevier (PMID): 40678255 ● Search Scopus @ Elsevier (DOI): 10.21203/rs.3.rs-6795517/v1 (DOI: 10.21203/rs.3.rs-6795517/v1, PubMed: 40678255)
2.	Kazuko Akashi, Yoshie Imai, Shingen Nakamura, Yusaku Maeda, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, Mamiko Takahashi, Shiroh Fujii, Takeshi Harada and Hirokazu Miki : Preparedness for the future in patients with relapsed or refractory hematopoietic malignancies in the treatment process: a qualitative study, Annals of Palliative Medicine, 14, 1, 43-56, 2025. (要約) This study aims to clarify how patients with relapsed or refractory (R/R) hematological malignancies prepare for the future and set treatment goals. R/R hematological malignancies often require intensive therapies, including stem cell transplantation and CAR-T cell therapy, which pose high risks of adverse events. Many patients continue aggressive treatment until the end of life for pain relief or even a potential cure, despite the significant symptom burden. Understanding each patient's treatment motivations and preferences is essential to aligning care with their individual values. By examining their experiences, current health status, and treatment goals, this study seeks to provide a basis for holding early discussions on future care, contributing to individualized decision-making support for patients facing limited treatment options and uncertain prognoses. A qualitative descriptive study design was used to conduct semi-structured interviews with 16 patients with relapsed/refractory hematopoietic malignancies who were hospitalized for chemotherapy. The four main themes expressed by the participants were (I) I want to live through the treatment until the end of my life because I know recovery is difficult; (II) my current treatment depends on how much my body can endure; (III) I want to keep trying, but I am at the limit of what I can do now; and (IV) I want to continue even if the treatment is limited because I think it will help someone else. Patients with hematopoietic malignancies who are undergoing treatment may be motivated by a variety of different factors to continue with treatment. Discussing patients' goals and wishes with respect to treatment is critically important to ensure that such treatment is aligned with patients' preferences. (キーワード) Humans / Hematologic Neoplasms / Male / Female / Middle Aged / Qualitative Research / Adult / Aged / Palliative Care (出版サイトへのリンク) ● Publication site (DOI): 10.21037/apm-24-124 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 39963757 ● Search Scopus @ Elsevier (PMID): 39963757 ● Search Scopus @ Elsevier (DOI): 10.21037/apm-24-124 (DOI: 10.21037/apm-24-124, PubMed: 39963757)

国内講演発表:

1.	曽我部公子, 藤井志朗, 大浦雅博, 原田武志, 三木浩和, 前田悠作, 八木ひかる (名), 住谷龍平, 中村信元, 松岡賢市 : 同種造血細胞移植が奏効した治療抵抗性肝脾T 細胞リンパ腫(HSTL)の2例, 第47回日本造血・免疫細胞療法学会総会, 2025年3月.
2.	藤井志朗, 曽我部公子, 前田悠作, 住谷龍平, 八木ひかる, 大浦雅博, 原田武志, 中村信元, 三木浩和, 松岡賢市 : 診断に苦慮したPh陽性B-ALL/LBLの1例, 第64回日本血液学会中国四国地方会, 2025年3月.
3.	大浦雅博, 中村信元, 前田悠作, 住谷龍平, 曽我部公子, 八木ひかる, 原田武志, 藤井志朗, 三木浩和, 河村若菜, 鎌田涼香, 樫地舞子, 三木こずえ, 小林誠司, 緒方良輔, 佐藤翔平, 市原知怜, 小松崇俊, 武田悠作, 近田優介, 斎藤貴, 古本みゆ, 井上貴久, 松岡賢市 : 外国人患者に対する造血幹細胞移植における「言語の壁」の克服, 第47回日本造血・免疫細胞療法学会総会, 2025年3月.
4.	森本くるみ, 玉谷香住里, 山本英之, 新居清美, 三木こずえ, 今井芳枝, 前田悠作, 住谷龍平, 大浦雅博, 曽我部公子, 八木ひかる, 原田武志, 藤井志朗, 中村信元, 三木浩和, 松岡賢市 : 同種造血幹細胞移植を受けた壮年期患者の原動力, 第47回日本造血・免疫細胞療法学会総会, 2025年3月.
5.	藤井志朗, 曽我部公子, 湯浅麻美, 西尾進, 前田悠作, 八木ひかる, 住谷龍平, 大浦雅博, 原田武志, 中村信元, 三木浩和, 松岡賢市 : 肝類洞閉塞症候群/肝中心静脈閉塞症の早期診断におけるHokUS-6の有用性の検討, 第47回日本造血・免疫細胞療法学会総会, 2025年3月.
6.	渡邊浩良, 岡村和美, 前田悠作, 住谷龍平, 大浦雅博, 原田武志, 中村信元, 三木浩和, 漆原真樹 : ROTEMによるインヒビター陽性血友病A患者のヒトFX加VIIa製剤及びrVIIa併用時の血液凝固機能評価, 日本血液学会学術集会, 274, 2024年10月.